233 related articles for article (PubMed ID: 27226215)
21. Vitamin D receptor and cellular retinol-binding protein-1 immunohistochemical expression in normal, hyperplastic and neoplastic endometrium: Possible diagnostic and therapeutic implications.
Badary DM; Abou-Taleb H
Ann Diagn Pathol; 2020 Oct; 48():151569. PubMed ID: 32805516
[TBL] [Abstract][Full Text] [Related]
22. Maspin expression, subcellular localization and clinicopathological correlation in endometrial hyperplasia and endometrial adenocarcinoma.
Blandamura S; Alessandrini L; Saccardi C; Giacomelli L; Fabris A; Borghero A; Litta P
Histol Histopathol; 2014 Jun; 29(6):777-83. PubMed ID: 24346847
[TBL] [Abstract][Full Text] [Related]
23. Enhanced CD24 expression in endometrial carcinoma and its expression pattern in normal and hyperplastic endometrium.
Kim KH; Choi JS; Kim JM; Choi YL; Shin YK; Lee HC; Seong IO; Kim BK; Chae SW; Kim SH
Histol Histopathol; 2009 Mar; 24(3):309-16. PubMed ID: 19130400
[TBL] [Abstract][Full Text] [Related]
24. Role of Morphometry and Matrix Metalloproteinase-9 Expression in Differentiating between Atypical Endometrial Hyperplasia and Low Grade Endometrial Adenocarcinoma.
Assaf MI; Abd El-Aal W; Mohamed SS; Yassen NN; Mohamed EA
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2291-2297. PubMed ID: 30139240
[TBL] [Abstract][Full Text] [Related]
25. Detection of PTEN immunoreactivity in endometrial hyperplasia and adenocarcinoma.
Tantbirojn P; Triratanachat S; Trivijitsilp P; Niruthisard S
J Med Assoc Thai; 2008 Aug; 91(8):1161-5. PubMed ID: 18788685
[TBL] [Abstract][Full Text] [Related]
26. Concurrent endometrial carcinoma following hysterectomy for atypical endometrial hyperplasia.
Hahn HS; Chun YK; Kwon YI; Kim TJ; Lee KH; Shim JU; Mok JE; Lim KT
Eur J Obstet Gynecol Reprod Biol; 2010 May; 150(1):80-3. PubMed ID: 20185225
[TBL] [Abstract][Full Text] [Related]
27. Differential diagnosis of endometrial hyperplasia and carcinoma by computerized image cytometry of cell proliferation, apoptosis and Bcl-2 expression.
Mora LB; Diaz JI; Cantor AB; Nicosia SV
Ann Clin Lab Sci; 1999; 29(4):308-15. PubMed ID: 10528831
[TBL] [Abstract][Full Text] [Related]
28. Utility of PTEN expression of endometrial "surface epithelial changes" and underlying atypical endometrial hyperplasia.
Quddus MR; Ologun BA; Sung CJ; Steinhoff MM; Lawrence WD
Int J Gynecol Pathol; 2009 Sep; 28(5):471-6. PubMed ID: 19696618
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical Study of Ki-67 in Hyperplastic and Endometrium Carcinoma: A Comparative Study.
Ghalib Farhood R; Abd Ali Al-Humairi I
Arch Razi Inst; 2022 Feb; 77(1):229-234. PubMed ID: 35891746
[TBL] [Abstract][Full Text] [Related]
30. Autophagy in endometrial carcinomas and prognostic relevance of 'stone-like' structures (SLS): what is destined for the atypical endometrial hyperplasia?
Sivridis E; Giatromanolaki A; Liberis V; Koukourakis MI
Autophagy; 2011 Jan; 7(1):74-82. PubMed ID: 21099253
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer.
Raffone A; Travaglino A; Saccone G; Cieri M; Mascolo M; Mollo A; Insabato L; Zullo F
APMIS; 2019 Sep; 127(9):597-606. PubMed ID: 31237034
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcome of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: institutional experience and review of literature.
Rakha E; Wong SC; Soomro I; Chaudry Z; Sharma A; Deen S; Chan S; Abu J; Nunns D; Williamson K; McGregor A; Hammond R; Brown L
Am J Surg Pathol; 2012 Nov; 36(11):1683-90. PubMed ID: 23073327
[TBL] [Abstract][Full Text] [Related]
33. CyclinD1, a prominent prognostic marker for endometrial diseases.
Liang S; Mu K; Wang Y; Zhou Z; Zhang J; Sheng Y; Zhang T
Diagn Pathol; 2013 Aug; 8():138. PubMed ID: 23947899
[TBL] [Abstract][Full Text] [Related]
34. Hysteroscopic view in atypical endometrial hyperplasias: A correlation with pathologic findings on hysterectomy specimens.
Garuti G; Mirra M; Luerti M
J Minim Invasive Gynecol; 2006; 13(4):325-30. PubMed ID: 16825075
[TBL] [Abstract][Full Text] [Related]
35. GLUT-1 Expression in Proliferative Endometrium, Endometrial Hyperplasia, Endometrial Adenocarcinoma and the Relationship Between GLUT-1 Expression and Prognostic Parameters in Endometrial Adenocarcinoma.
Canpolat T; Ersöz C; Uğuz A; Vardar MA; Altintaş A
Turk Patoloji Derg; 2016; 32(3):141-7. PubMed ID: 27562387
[TBL] [Abstract][Full Text] [Related]
36. Performance Characteristics of Endometrial Sampling in Diagnosis of Endometrial Carcinoma.
Taraboanta C; Britton H; Plotkin A; Azordegan N; Clement PB; Gilks CB
Int J Gynecol Pathol; 2020 Jan; 39(1):19-25. PubMed ID: 31815891
[TBL] [Abstract][Full Text] [Related]
37. Nuclear expression of β-catenin in endometrial hyperplasia as marker of premalignancy.
Travaglino A; Raffone A; Saccone G; Mascolo M; D'Alessandro P; Arduino B; Mollo A; Insabato L; Zullo F
APMIS; 2019 Nov; 127(11):699-709. PubMed ID: 31403731
[TBL] [Abstract][Full Text] [Related]
38. PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia.
Allison KH; Upson K; Reed SD; Jordan CD; Newton KM; Doherty J; Swisher EM; Garcia RL
Int J Gynecol Pathol; 2012 Mar; 31(2):151-159. PubMed ID: 22317873
[TBL] [Abstract][Full Text] [Related]
39. Pax2 expression in simultaneously diagnosed WHO and EIN classification systems.
Joiner AK; Quick CM; Jeffus SK
Int J Gynecol Pathol; 2015 Jan; 34(1):40-6. PubMed ID: 25473752
[TBL] [Abstract][Full Text] [Related]
40. Prognostic markers for coexistent carcinoma in high-risk endometrial hyperplasia with negative D-score: significance of morphometry, hormone receptors and apoptosis for outcome prediction.
Ørbo A; Kaino T; Arnes M; Larsen K; Pettersen I; Moe B
Acta Obstet Gynecol Scand; 2009; 88(11):1234-42. PubMed ID: 19900140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
